This site is intended for healthcare professionals

Pivotal phase III IMpower010 study data show Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning- Genentech/Roche

Read time: 1 mins
Last updated:20th May 2021
Published:20th May 2021
Genentech, a member of the Roche Group announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq (atezolizumab) following surgery and chemotherapy reduced the risk of disease recurrence or death (disease-free survival; DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50-0.88) in people with Stage II-IIIA non-small cell lung cancer (NSCLC), whose tumors express PD-L1?1%, compared with best supportive care (BSC).
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest